Multiple myeloma is a type of cancer characterized by the uncontrolled proliferation of clonal plasma cells, which leads to organ dysfunction and, eventually, death. There were more than 33,000 ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its 2024 Annual Results. Business Highlights Zevor-cel was ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T ...

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...

It is a CAR-T (chimeric antigen receptor T-cell) therapy, where a patient’s ... a proteasome inhibitor and an anti-CD38 antibody such as Janssen’s Darzalex (daratumumab).

The bispecific antibody targets GPRC5D – which is overexpressed on myeloma cells ... which includes CD38 antibody Darzalex (daratumumab) and two BCMA-targeting therapies, CAR-T Carvykti ...

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...